Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$23.49 – $41.33
100% from low
Exchange
NASDAQ
ETF
No company description on file.
No one on the platform currently holds CANC.
No tracked institution reports a position in CANC as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-10 | $0.0196 | 2025-12-11 |
| 2024-12-11 | $0.7283 | 2024-12-12 |
| 2023-12-13 | $0.1491 | 2023-12-15 |
No one on the platform has traded CANC yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76% $CELC $CANC $XBI https://stocktwits.com/news/equity/markets/celcuity-become-acquisition-target-celc-stock-soars-why-wall-street-bullish/cZQMp2xReJ2
View on StockTwits ↗$CUE reminder https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-host-virtual-r-120000426.html Why the Doctors are the "Secret Weapon" Most retail traders are staring at the $0.18 price and panicking about the split. They aren't reading the fine print about Dr. DiPaolo and Dr. Kay. • The "Science" Validation: These are not "hired guns." They are independent experts from Saint Louis University and UMass. If the science was failing, these men would not risk their reputations by speaking at a "Virtual R&D Day" for a micro-cap stock. • The "J&J" Connection: With Lucinda Warren (24 years at J&J) running the call, these doctors are effectively her "expert witnesses" to show Big Pharma that CUE-401 is a legitimate breakthrough. $ABBV $PFE $CANC
View on StockTwits ↗Why Did GLUE Stock Surge Over 50% In Premarket Today? $GLUE $BBC $CANC $XBI https://stocktwits.com/news/equity/markets/why-did-glue-stock-surge-over-50-in-premarket-today-1/cmxzbnHR42E
View on StockTwits ↗$CANC What matters next is the company’s ability to build a predictable delivery rhythm. The business must show that scaling does not introduce uncontrolled risk. Visible traction across segments would strengthen the thesis. Over time, credibility will hinge on repeatable performance.
View on StockTwits ↗AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK $AUTL $BMED $CANC https://stocktwits.com/news/equity/markets/autl-stock-soars-pre-market-on-position-recommendation-for-cell-therapy-targeting-cancer-in-uk/cL52LfPREXA
View on StockTwits ↗#Healthcare #ETFs For The Weight-Loss Drug Boom And Beyond $WELD $HRTS $CANC https://talkmarkets.com/content/etfs/healthcare-etfs-for-the-weight-loss-drug-boom-and-beyond?post=440169
View on StockTwits ↗Tema Oncology ETF announces dividend of $0.1491. Payable on 12/15/2023. www.marketbeat.com/stocks/NASDAQ/CANC/dividend/ $CANC
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.